\ o \ 00 " sn y itt TRADE SECRET Study Title H-24743: Biopersistence Screening 10-Dose Oral Gavage Study in Rats Laboratory Project ID : DuPont-1155 8 DuPont-11558 Author: Carol Finlay, B.A.

AR226-3393 HASKELL LABORATORY C4, C6 PERFLUORODIIODOALKANE EMERGENCY EXPOSURE LIMIT EEL: 50 ppb (1-60 minutes) Time Limit: 60 minutes Ceiling Concentration: 50 ppb Emergency Exposure Limits (EELs) are to be used for emergency planning purposes only.

AfUAG- 3lf7 / 0 a*K 000152 ftW 6 - RESEARCH i Prets Research.

AlU siel 36U ADVANCE UNEDITED DRAFT DRAFT RISK PROFILE OUTLINE EXECUTIVE SUMMARY 1 1NTRODUCTION 1.1 Chemical Identity of the proposed substance Mention who has made the proposal and when Spell out the specific chemical identity and particular considerations related to that 1.2 Conclusion of the POP Review Committee of Annex D information "POP RC has evaluated Annex D (add reference to the meeting and the decision) information and has concluded that ..." 1.3 Data sources short overview of the data sources provided by the proposing Party and/or used by the POP RC in Annex D screening short overview of data submitted by Parties and observers (NB: a more elaborated summary of the submissions may be provided as a separate POP RC INF document) information on availability of national and international assessment reports; [1.4 Summary of available risk information brief summary of the submitted evaluations and other information referred to in Annex E, point f ' Alternatively, can be summarised in a separate POP RC INF document ] 1.5 Status of the chemical under international conventions 2 SUMMARY INFORMATION RELEVANT FOR THE RISK PROFILE 2.1 Sources production, trade, stockpiles uses releases to the environment 2.2 Environmental fate Further elaboration of information referred to in Annex D, paragraphs (b) - (d); based on all relevant available information ' Monitoring data available integrated under the subheading or alternatively dealt with under separate heading "Monitoring data" Could be split in: 2.2.1 Persistence 2.2.2 Bioaccumulation 2.2.3 Long range environmental transport 000222 P-2 2.3 Exposure Summary of relevant information concerning exposure in local areas (both near the source and in remote areas) Summary of relevant information concerning exposure as a result of LRET Information on bioavailability 2.4 Hazard assessment for endpoints of concern Further elaboration of information referred to in Annex D, paragraph (e); based on all relevant available information Monitoring data on effects included 3 SYNTHESIS OF THE INFORMATION synthesis of the information under chapter 2 that focus on information that is leading to the conclusive statement under chapter 4 4 CONCLUDING STATEMENT Is the chemical likely, as a result of LRET, to lead to significant adverse human health and/or environmental effects, such that global action is warranted Note: No Annexes; all other data provided as POP RC INF documents Target size not longer than 20 pages 2 000223

Katherine E.

A f . 2 . i > 6 f c/ exhibit a P-2 Weekly Morbidity and Mortality Weekly Report ___________May 5, 2006 /Vol. 55 / No. 17 State Prevalence of Self-Reported Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation -- United States, 2003 Arthritis is costly ($86 billion annually), highly prevalent (affecting 43 million U.S. adults), the leading cause of dis ability, and associated with substantial disparities in pain, activity limitations, and compromised quality of life (1- 3).

3M General Offices September 21, 2006 3M Center St.

M - 37,0 C; -- WASHINGTON WORKS C-8 INDUSTRIAL HYGIENE A.

KStaatfhf eVriicneePEre. sRideeendt, Ph.D. 3SMafeEtynOvirpoenramtieonntsal, Health and 96PS50tO.10PBB7ao7uux8ls,h34M33A3N3v13e51n5u1e3, 3B-3u3il3d1ipng. 142-2E-26 %Er'tL-(y707-& 3 72> /tezz -37^6 L# Certified Mail June 6,2007 DEOUW12PSfoaf0Acis0EcuheEPmiPnAaoeegsnfnttnotP-snPoyRlrDllovuoCcatoeinmos2insa0i64nPA46gr2v0eC8ev-0neeA0unn0ettttie1noNr:nWSaencdtiTonox8i(ces) CONTAIN NO CBI 89070000329 9 o ; o o o (T~Y NO CBI f- < Re: TSSulCfoAna8t(ee-)baSsuebdstaanndtiaClaRrbisokxyNlioct-ibcea:seSdupFpluleomroecnhteaml tiocaDlsocket No. 8EHQ-0598-373; To whom it may concern: t3oodddlhiMobeufmyftsjrsereiiepontrrcseemrigtddicionvi,egfnfgenteuer0tsafon.ltt1oyncafhlsttetloriiihoeooereiwcnnnsf0efti.sasine3vettncguufemdtfddsdeeyyglxcoaa/ptwcikfdnootgeaarsnrx/satudaipfmorttatoosenyofsciodutdnaooefrinandrettldehdaornreuscmenohctpmititomvonerwoirdeeatttsyethtofeudheranrloerntnamptatdiponoltohhtaaPtaaeaennnFsbndsyhOoititiirununSgaamelaehlodtueo(inupgrsofoatreanPittrvdnaoFfiaogllxnOugstigeohcemSe)ryoeaostrdfloftooefaecie1stivditc.n.oa0etdsnlnomuitenapcatgesnmuF/udskn1el.g-fenlgoa/uEtdencarxantoalaypettnteoorieoaoxs(untnuPiirclo,roFyenaetOoanftoofSxdvefi)fcPect.sotriFpstyTyOriihnSnaengdat Tom0eamnv.bi1eimdascm,elrveu0roo-ava.sm3rgtacyi,itooanioeontpaervnsildca1pwbl.feau0aeextatemrmatteneimaocrgclynyi/eonk)sn(agrFwwdat/iOtdueoesacrBrnewytee)oee,dpdvfr,aeueatcrrahlfoiaunyonudadrrgtmsometiigindiedcned.dssiis,.stcTtattaaehhtItrinroyytoelrrrenadsoodirioapdddenofisdtsctppiateohortslhunynlsr,csispouitebcurum,roargalelloihiPdnfaceFelnowravOdamceetStlifoiaoougttdpnionhoamrctaintlaaesiyodncsnatnadtbiyyv(ywp,bi(otoaaeLytlrnrea,aDednnla)otengaivp2adnaarl0avell.lnaeupygaeausrueFttineisruaadionnoltpcgvfsdateiTotiaaphosnSanoedHrlaaolletgliveoievcnlaesllso.f FapbfeaoToainfctynabuhntftdtsrneediemPievccribnmNrenittaucvtisgteyDoywteesamwndrcebinao1enoorlilar3reenrutel,yochntnmtbho1eltroaissa7eamnFPen,aoladreFiitg2tnvtmhs1OeemmdaesdietSroenaainio.talrtnoedttennh6sMeswbape1atclaroi.garaatn1beshteird.eTtnaa0tnraiPsthfcnatwnemFeeeltademrarOeigly-enliw/raSgbkdewptlho.ehgelaatdaiesey/,rgItdryanedehln(amedwPutuyannreNamdeeogigttnfditeDbrfghcagiroeethh,)tsicutrt,otaoaht1spnsonsire7ntwg,fa,owampetsrnrewhasirtrecdelethemensoi-trenhetmdohrareTeoetnaiwposncfbSdaaprerbi/FHnreortoaea]ueancrdilsoamnsatnpetiritnciovvdooantroiehslegPtwptetnyayh-FsrtesirweeotOeiosohpnsecirtSuid,ahoensft-nteisniergattawiechmotntllliaueetigasaamnssrrttlelrtidepesemcpdeaesenahann.rxiltcrinidvsoalcsPagititdioraotnFigoasonmliaOnocbnntnwibragimSfyolalueyii-lcetnrlrdoyaaetnedgorh,tnltrosuaavioclwanretntaeueygtaaegwpederifrimr.nnfeennleiraoetanechlvltgtoeeerld / 3S| P-2 t1h.0e hmiggh/kegs/tddaoysedocshaogseengrwouasp arpelpartoivperitaoteclyonetfrfoelcstidvueriinngptrhoedulaccitnagtioann pefefreioctd.inTmhaisteirnndailcraattess. that tAohnletgho8oi(une)gghdwotohcrkekseetbadysaUtaa.Ssdu.opEpnPloeAtmmteoeneattstsothepsesre`fsvluuiboosurtosacnshutiebamml iricissaskliso'.nresT.phoerrtienfogrteh,rwesehoarlde,pwlaecirnegcotghneiszeerethseults in Trwehiplelorbinte-ilsfiofperewnpaodrridntiegodnintoocfltuhthseiiosEnsPtoAufdoryensicsuelctiostmfirsporlmeecteeainavanelddy.saisdroaffpt hfianraml arecpookrint ehtaics bsaemenplperso.duTcheed.finTahlerefpinoarlt (I6f5y1o)u7h3a7v-e13a7n4y.questions or need additional information, please contact Deanna Luebker at Sincerely, ^ KStaatfhfeVriincee EP.reRseideednt, Environmental, Health and Safety Operations

Jean B.

3M ENVIRONMENTAL LABORATORY REPORT NO. 07-0650 Final Report Analysis of PFBA, PFOA, PFBS, PFOS, FBSA, and FOSA in Aqueous Samples from 3M Decatur, Alabama 3M Decatur NPDES Permit Number AL0000205: Quarterly FC Monitoring of Outfall DSN001; 4th Quarter 2007 Sampling Laboratory Request Number: E07-0650 Method Requirement: 3M Method ETS-8-154.1 Report Date -December 10, 2007 Testing Laboratory 3M EHS Operations 3M Environmental Laboratory Building 260-5N-17 Maplewood, MN 55144-1000 Requester Gary Hohenstein 3M Building 42-02-E-27 PO Box 3331 Saint Paul, MN 55133-3331 Phone: (651)778-5150 Fax: (651)778-7203 1ir accredited] Certificate #2052-01 The testing reported herein meet the requirements of ISO/IEC17025-2005 "General Requirements for the Competence of Testing and Calibration Laboratories", in accordance with the A2LA Certificate #2052-01.

-f\ R o iQ _ o s rs ~ PFOS Pharmacokinetic - 7 000223 C O V iH tfc I ^ the development services company Covane Laboratories Inc.

AR N-Et FOSE alcohol IAcute Toxicity - 0002S8 International Research and Development Corporation SPONSOR: TEST MATERIAL: SUBJECT: 3M Company FM-3422 Acute Oral Toxicity (LD,n) Study in Rats.

AR Z 6 - 0 3 * 0 ACTIVATED SLUDGE RESPIRATION INHIBITION TEST TEST SUBSTANCE_______________________________________________ Identity: A mixture containing perfluorooctanesulfbnate, whichmay also be referred to as PFOS, FC-95, or as a component of FX-3104. (1Octanesulfonic acid) (CAS # 2795-39-3).

Katherine E.